EA201690680A1 - Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма - Google Patents

Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма

Info

Publication number
EA201690680A1
EA201690680A1 EA201690680A EA201690680A EA201690680A1 EA 201690680 A1 EA201690680 A1 EA 201690680A1 EA 201690680 A EA201690680 A EA 201690680A EA 201690680 A EA201690680 A EA 201690680A EA 201690680 A1 EA201690680 A1 EA 201690680A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gamma
interferon
minicoles
aimed
loaded
Prior art date
Application number
EA201690680A
Other languages
English (en)
Other versions
EA032740B1 (ru
Inventor
Химансху Брахмбхатт
Дженнифер Макдиармид
Original Assignee
Энджинеик Молекьюлар Деливери Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энджинеик Молекьюлар Деливери Пти Лтд. filed Critical Энджинеик Молекьюлар Деливери Пти Лтд.
Publication of EA201690680A1 publication Critical patent/EA201690680A1/ru
Publication of EA032740B1 publication Critical patent/EA032740B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлены композиции и способы для лечения злокачественных опухолей. Методология влечет за собой, например, введение пациенту с раком первой композиции, содержащей множество полученных из бактерий интактных миниклеток или интактных убитых бактериальных клеток, каждая из которых содержит противораковое средство и несет биспецифический лиганд на поверхности, лиганд, обладающий специфичностью к компоненту клетки млекопитающего, и второй композиции, содержащей интерферон-гамма (IFN-гамма) или средство, которое повышает экспрессию IFN-гамма у индивидуума. Композиции включают первую композицию и вторую композицию, как описано, необязательно с дополнительным противораковым средством.
EA201690680A 2013-10-04 2014-10-03 Способ лечения опухоли у индивидуума и набор для осуществления способа EA032740B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887258P 2013-10-04 2013-10-04
PCT/IB2014/002824 WO2015049589A1 (en) 2013-10-04 2014-10-03 Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Publications (2)

Publication Number Publication Date
EA201690680A1 true EA201690680A1 (ru) 2016-07-29
EA032740B1 EA032740B1 (ru) 2019-07-31

Family

ID=52777107

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690680A EA032740B1 (ru) 2013-10-04 2014-10-03 Способ лечения опухоли у индивидуума и набор для осуществления способа

Country Status (17)

Country Link
US (2) US9731011B2 (ru)
EP (1) EP3052122A4 (ru)
JP (1) JP6538031B2 (ru)
KR (1) KR102433719B1 (ru)
CN (1) CN105658233B (ru)
AP (1) AP2016009153A0 (ru)
AU (1) AU2014330895B2 (ru)
BR (1) BR112016007100A2 (ru)
CA (1) CA2926161C (ru)
EA (1) EA032740B1 (ru)
HK (1) HK1223281A1 (ru)
IL (1) IL244851B (ru)
MX (1) MX2016004285A (ru)
NZ (1) NZ718148A (ru)
SG (1) SG11201602429QA (ru)
TW (1) TWI737576B (ru)
WO (1) WO2015049589A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016004285A (es) * 2013-10-04 2016-07-08 Engeneic Molecular Delivery Pty Ltd Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
SG11201702627UA (en) * 2014-10-03 2017-04-27 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
SG11201902940RA (en) * 2016-10-06 2019-05-30 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
JP2021532106A (ja) * 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
SG11202107306WA (en) * 2019-01-04 2021-08-30 Engeneic Molecular Delivery Pty Ltd Encapsulated glycolipid antigens for treatment of neoplastic diseases
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2023518484A (ja) * 2020-03-24 2023-05-01 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド コロナウイルス感染症を含むウイルス感染症を治療および／または予防するための組成物およびワクチン、並びにそれらの使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2315067B (en) 1996-07-11 2000-02-16 Pharmacia Spa Morpholinyl anthracycline derivatives
PL360581A1 (en) 1999-05-11 2004-09-06 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
EP1231943A1 (en) * 1999-11-12 2002-08-21 Maxygen Holdings Ltd Interferon gamma conjugates
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
PT2302063T (pt) 2001-10-15 2016-07-28 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
EP1594547A2 (en) * 2003-02-14 2005-11-16 University Of South Florida Research Foundation, Inc. Chitosan-microparticles for ifn gene delivery
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
NZ547983A (en) * 2003-12-09 2009-05-31 Engeneic Molecular Delivery Pty Ltd Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
SI1718338T1 (sl) * 2004-02-02 2015-09-30 Engeneic Molecular Delivery Pty Ltd. Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic
CA2803995C (en) 2004-08-26 2014-06-10 Engeneic Molecular Delivery Pty Ltd. Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
AU2005276145C1 (en) 2004-08-26 2011-01-06 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
LT2712618T (lt) 2006-06-23 2017-02-27 Engeneic Molecular Delivery Pty Ltd. Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles
CN101715489B (zh) 2007-03-30 2016-05-25 因詹尼克分子递送控股有限公司 用于体内递送至哺乳动物细胞的、包含无质粒的功能性核酸的、源自细菌的完整小细胞
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
US9844598B2 (en) * 2011-12-13 2017-12-19 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
AU2013327059B2 (en) * 2012-10-02 2018-11-08 Vaxiion Therapeutics, Llc Immunomodulatory minicells and methods of use
MX2016004285A (es) * 2013-10-04 2016-07-08 Engeneic Molecular Delivery Pty Ltd Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.

Also Published As

Publication number Publication date
AU2014330895A1 (en) 2016-04-14
CN105658233A (zh) 2016-06-08
HK1223281A1 (zh) 2017-07-28
US10500277B2 (en) 2019-12-10
KR20160058885A (ko) 2016-05-25
SG11201602429QA (en) 2016-04-28
IL244851A0 (en) 2016-05-31
US20150098897A1 (en) 2015-04-09
AU2014330895B2 (en) 2019-08-15
TWI737576B (zh) 2021-09-01
KR102433719B1 (ko) 2022-08-17
EP3052122A1 (en) 2016-08-10
EA032740B1 (ru) 2019-07-31
WO2015049589A1 (en) 2015-04-09
IL244851B (en) 2020-04-30
CA2926161C (en) 2023-03-14
MX2016004285A (es) 2016-07-08
AP2016009153A0 (en) 2016-04-30
US20170326235A1 (en) 2017-11-16
US9731011B2 (en) 2017-08-15
NZ718148A (en) 2022-02-25
JP2016532639A (ja) 2016-10-20
CN105658233B (zh) 2020-09-04
EP3052122A4 (en) 2017-05-17
JP6538031B2 (ja) 2019-07-03
TW201601748A (zh) 2016-01-16
BR112016007100A2 (pt) 2017-08-01
CA2926161A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
EA201690680A1 (ru) Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма
MY197324A (en) Adenovirus armed with bispecific t cell activator
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
PH12017500787A1 (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
BR112017008972A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra carcinoma hepatocelular (hcc) e outros cânceres
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MA39907A (fr) Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam)
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
NZ609201A (en) Means and methods for treating dlbcl
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
MX2014013763A (es) Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
SG194753A1 (en) Induction of il-12 using immunotherapy